Watson Pharmaceuticals, Inc. (WPI: Quote) confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application, or ANDA, with the U.S. Food and Drug Administration, or FDA, seeking approval to market Metformin Hydrochloride Extended-release Tablets USP, 1000 mg.
Watson's Metformin Hydrochloride Extended-release Tablets are a generic version of Depomed, Inc.'s Glumetza. Glumetza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Click here to receive FREE breaking news email alerts for Actavis Plc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com